Boehringer Ingelheim, an Ingelheim, Germany-based market leader in animal health, acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company.
The amount of the deal was not disclosed.
Led by Jan Spaas, CEO, GST is dedicated to the research, development and production of evidence-based, regenerative medicines (stem cell therapies) used to treat orthopedic and metabolic diseases in animals.
Boehringer Ingelheim already entered into a partnership with GST in 2018; in 2019, the companies launched Arti-Cell® Forte in Europe.
Arti-Cell® Forte is a stem cell product in the veterinary world granted marketing authorization by the European Commission. The acquisition and integration of GST will accelerate the development pipeline of Boehringer Ingelheim.